Preparation and preliminary biological evaluation of [153Sm] samarium AMD3100; towards a possible therapeutic chemokine receptor CXCR4 targeting complex

Authors

  • Ali Bahrami-Samani Nuclear Science Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
  • Ali Khalaj Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Amir Reza Jalilian Nuclear Science Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
  • Ayuob Aghanejad Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran AND Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Davood Beiki Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran AND Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Stephan Maus Clinic of Nuclear Medicine, University Medical Centre Mainz, Langenbeckstrasse 1, D-55131 Mainz, Germany
Abstract:

Introduction: In continuation of recent development of possible C-X-C chemokine receptor type 4 (CXCR4) imaging agents, we report the development of a possible CXCR4 targeted therapy agent. Methods: [153Sm]labeled 1,1′-[1,4-phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclo -tetradecane ([153Sm]-AMD3100) was prepared using [153Sm]SmCl3 and AMD-3100 for 24h at 50°C in acetate buffer.Stability tests, partition coefficient determination, toxicity tests and biodistribution studies of the complex in wild-type rats were determined. Results: The radiolabeled complex was prepared in high radiochemical purity (>95%; RTLC and >99% HPLC) and specific activity of 278 GBq/mmol and demonstrated significant stability up to 48h at 37 °C (in presence of human serum). Partition coefficient determination was calculated Log P= -1.09.Hepatotoxicity experiments demonstrated no distinguishable effect on hepatic enzymes in 10 days post injection.Initial complex biodistribution data showed significant liver and kidney accumulation in wild-type rats. Conclusion: Since lung and spleen are considered as CXCR4 rich organs, the best lung/blood and spleen/blood ratios were achieved 12 and 7 at 24 h post injection. Further investigations are needed especially on therapeutic properties of this agent.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

preparation and preliminary biological evaluation of [153sm] samarium amd3100; towards a possible therapeutic chemokine receptor cxcr4 targeting complex

introduction: in continuation of recent development of possible c-x-c chemokine receptor type 4 (cxcr4) imaging agents, we report the development of a possible cxcr4 targeted therapy agent. methods: [153sm]labeled 1,1′-[1,4-phenylenebis(methylene)] bis-1,4,8,11-tetraazacyclo -tetradecane ([153sm]-amd3100) was prepared using [153sm]smcl3 and amd-3100 for 24h at 50°c in acetate buffer.stability ...

full text

Preparation of a 153Sm-5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin complex as a possible therapeutic agent

Introduction: Porphyrins are interesting derivatives with low toxicity, tumor avidity and rapid wash-out suggested as potential radiopharmaceuticals in radiolabeled form. In this work we report, synthesis, radiolabeling, quality control, stability, partition coefficient determination and biodistribution studies of 153Sm-5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin (153Sm-4-MPP) in ...

full text

Synthesis and Evaluation of [67Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4

In order to develop a possible C-X-C chemokine receptor type 4 (CXCR4) imaging agent for oncological scintigraphy, [(67)Ga]-labeled 1,1'-[1,4-Phenylene-bis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane) ([(67)Ga]-AMD3100) was prepared by using [(67)Ga]GaCl3 and AMD-3100 for 2 h at 50 °C (radiochemical purity: >95% ITLC, >99% HPLC, specific activity: 1800-2000 TBq/mmol) in acetate buffer. The...

full text

Development of 153Sm/177Lu-EDTMP as a possible therapeutic complex

Introduction:Targeted radionuclide therapy (TRT) has been demonstrated to be an effective therapeutic tool in patients with disseminated bone metastasis. TRT is generally performed with a single radionuclide. In this study we investigated the feasibility of combined TRT with a high-energy beta emitter (153Sm) and a low energy beta emitter (177Lu) in wistar...

full text

Preparation and quality control of 153Sm-[tris(1,10 -phenanthroline) samarium (III)] complex

Background: The 153Sm-[tris(1,10-phenanthroline) Samarium(III)]complex (153Sm-PL3) was prepared in view of development of targeting therapeutic compounds for malignancies, and interesting in-vitro anti-tumor activities of lanthanide phenanthroline complexes,. Materials and Methods: Sm-153 chloride was obtained by thermal neutron flux (4 × 1013 n.cm-2.s-1) of enriched 152Sm2O3 sample, diss...

full text

Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer.

Anaplastic thyroid carcinoma (ATC) is a rare thyroid cancer type with an extremely poor prognosis. Despite appropriate treatment, which includes surgery, radiotherapy, and chemotherapy, this cancer is invariably fatal. CXCR4 is the receptor for the stromal cell-derived factor-1 (SDF-1)/CXCL12 chemokine and it is expressed in a variety of solid tumors, including papillary thyroid carcinoma. Here...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 23  issue 1

pages  36- 43

publication date 2015-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023